Annual EBITDA
-$15.46 M
+$21.72 M+58.41%
December 31, 2023
Summary
- As of February 23, 2025, APRE annual EBITDA is -$15.46 million, with the most recent change of +$21.72 million (+58.41%) on December 31, 2023.
- During the last 3 years, APRE annual EBITDA has risen by +$37.12 million (+70.59%).
- APRE annual EBITDA is now -198167.95% below its all-time high of -$7800.00, reached on December 1, 2004.
Performance
APRE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$4.09 M
-$250.00 K-6.51%
September 30, 2024
Summary
- As of February 23, 2025, APRE quarterly EBITDA is -$4.09 million, with the most recent change of -$250.00 thousand (-6.51%) on September 30, 2024.
- Over the past year, APRE quarterly EBITDA has stayed the same.
- APRE quarterly EBITDA is now -54.31% below its all-time high of -$2.65 million, reached on December 31, 2022.
Performance
APRE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$14.75 M
-$570.20 K-4.02%
September 30, 2024
Summary
- As of February 23, 2025, APRE TTM EBITDA is -$14.75 million, with the most recent change of -$570.20 thousand (-4.02%) on September 30, 2024.
- Over the past year, APRE TTM EBITDA has stayed the same.
- APRE TTM EBITDA is now -403.55% below its all-time high of -$2.93 million, reached on September 30, 2018.
Performance
APRE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
APRE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +58.4% | 0.0% | 0.0% |
| 3 y3 years | +70.6% | 0.0% | 0.0% |
| 5 y5 years | +6.2% | 0.0% | 0.0% |
APRE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +58.4% | -54.3% | +81.7% | -5.4% | +69.0% |
| 5 y | 5-year | at high | +70.6% | -54.3% | +81.7% | -5.4% | +72.0% |
| alltime | all time | <-9999.0% | +70.6% | -54.3% | +81.7% | -403.6% | +72.0% |
Aprea Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$4.09 M(+6.5%) | -$14.75 M(+4.0%) |
| Jun 2024 | - | -$3.84 M(+22.2%) | -$14.18 M(+1.4%) |
| Mar 2024 | - | -$3.14 M(-14.3%) | -$13.99 M(-9.6%) |
| Dec 2023 | -$15.46 M(-58.4%) | -$3.67 M(+4.2%) | -$15.46 M(+7.0%) |
| Sep 2023 | - | -$3.52 M(-3.6%) | -$14.45 M(-4.1%) |
| Jun 2023 | - | -$3.65 M(-21.0%) | -$15.06 M(-55.4%) |
| Mar 2023 | - | -$4.62 M(+74.3%) | -$33.79 M(-9.1%) |
| Dec 2022 | -$37.19 M(+0.0%) | -$2.65 M(-35.9%) | -$37.18 M(-12.1%) |
| Sep 2022 | - | -$4.14 M(-81.5%) | -$42.29 M(-11.0%) |
| Jun 2022 | - | -$22.38 M(+179.4%) | -$47.52 M(+35.5%) |
| Mar 2022 | - | -$8.01 M(+3.2%) | -$35.07 M(-5.7%) |
| Dec 2021 | -$37.17 M(-29.3%) | -$7.76 M(-17.1%) | -$37.17 M(-14.7%) |
| Sep 2021 | - | -$9.36 M(-5.8%) | -$43.58 M(-6.1%) |
| Jun 2021 | - | -$9.94 M(-1.7%) | -$46.40 M(-8.8%) |
| Mar 2021 | - | -$10.11 M(-28.6%) | -$50.89 M(-3.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | -$52.58 M(+79.0%) | -$14.17 M(+16.3%) | -$52.58 M(+4.4%) |
| Sep 2020 | - | -$12.18 M(-15.6%) | -$50.34 M(+11.1%) |
| Jun 2020 | - | -$14.43 M(+22.3%) | -$45.32 M(+23.2%) |
| Mar 2020 | - | -$11.80 M(-1.0%) | -$36.80 M(+25.3%) |
| Dec 2019 | -$29.37 M(+78.2%) | -$11.93 M(+66.7%) | -$29.37 M(+27.2%) |
| Sep 2019 | - | -$7.16 M(+21.1%) | -$23.09 M(+22.4%) |
| Jun 2019 | - | -$5.91 M(+34.9%) | -$18.86 M(+45.6%) |
| Mar 2019 | - | -$4.38 M(-22.3%) | -$12.95 M(+51.1%) |
| Dec 2018 | -$16.48 M(+4.0%) | -$5.64 M(+92.6%) | -$8.57 M(+192.6%) |
| Sep 2018 | - | -$2.93 M | -$2.93 M |
| Dec 2017 | -$15.84 M(+407.0%) | - | - |
| Jun 2008 | -$3.13 M(-41.5%) | - | - |
| Jun 2007 | -$5.34 M(-31.4%) | - | - |
| Jun 2006 | -$7.78 M(>+9900.0%) | - | - |
| Dec 2004 | -$7800.00 | - | - |
FAQ
- What is Aprea Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Aprea Therapeutics?
- What is Aprea Therapeutics annual EBITDA year-on-year change?
- What is Aprea Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Aprea Therapeutics?
- What is Aprea Therapeutics quarterly EBITDA year-on-year change?
- What is Aprea Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Aprea Therapeutics?
- What is Aprea Therapeutics TTM EBITDA year-on-year change?
What is Aprea Therapeutics annual EBITDA?
The current annual EBITDA of APRE is -$15.46 M
What is the all time high annual EBITDA for Aprea Therapeutics?
Aprea Therapeutics all-time high annual EBITDA is -$7800.00
What is Aprea Therapeutics annual EBITDA year-on-year change?
Over the past year, APRE annual EBITDA has changed by +$21.72 M (+58.41%)
What is Aprea Therapeutics quarterly EBITDA?
The current quarterly EBITDA of APRE is -$4.09 M
What is the all time high quarterly EBITDA for Aprea Therapeutics?
Aprea Therapeutics all-time high quarterly EBITDA is -$2.65 M
What is Aprea Therapeutics quarterly EBITDA year-on-year change?
Over the past year, APRE quarterly EBITDA has changed by $0.00 (0.00%)
What is Aprea Therapeutics TTM EBITDA?
The current TTM EBITDA of APRE is -$14.75 M
What is the all time high TTM EBITDA for Aprea Therapeutics?
Aprea Therapeutics all-time high TTM EBITDA is -$2.93 M
What is Aprea Therapeutics TTM EBITDA year-on-year change?
Over the past year, APRE TTM EBITDA has changed by $0.00 (0.00%)